Skip to main content

Drug Interactions between boceprevir and Dutrebis

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

raltegravir boceprevir

Applies to: Dutrebis (lamivudine / raltegravir) and boceprevir

Coadministration of boceprevir and raltegravir may have modest effects on the pharmacokinetics of both drugs. The mechanism of interaction has not been established. When boceprevir 800 mg every 8 hours and raltegravir 400 mg every 12 hours were given together for 6 days, mean boceprevir peak plasma concentration (Cmax) and systemic exposure (AUC) were not significantly altered, but trough plasma concentration (Cmin) decreased by 26%. Likewise, boceprevir 800 mg three times a day for 10 days reduced the Cmin of a single 400 mg dose of raltegravir by 25%. These changes are not considered clinically significant. No dosage adjustment is required for boceprevir or raltegravir.

References (2)
  1. (2007) "Product Information. Isentress (raltegravir)." Merck & Co., Inc
  2. (2011) "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation

Drug and food interactions

Moderate

boceprevir food

Applies to: boceprevir

ADJUST DOSING INTERVAL: Food significantly enhances the oral bioavailability of boceprevir. When given at 800 mg three times daily with food, boceprevir exposure increased by up to 65% relative to administration in the fasting state. The bioavailability of boceprevir was similar regardless of meal type (e.g., high-fat versus low-fat) or whether taken 5 minutes prior to eating, during a meal, or immediately following completion of the meal. Therefore, boceprevir may be taken without regard to either meal type or timing of the meal.

MANAGEMENT: To ensure maximal oral absorption, boceprevir should be administered with a meal or light snack.

References (1)
  1. (2011) "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer